Resource Summary Report

Generated by RRID on Sep 8, 2026

MNNG/HOS Cl #5

RRID:CVCL_0439
Type: Cell Line

Proper Citation

RRID:CVCL_0439

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0439

Proper Citation: RRID:CVCL_0439

Description: Cell line MNNG/HOS Cl #5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Osteosarcoma

Defining Citation: PMID:265298, PMID:833871, PMID:1385192, PMID:2823272, PMID:2978869, PMID:3335022, PMID:3518877, PMID:6254071, PMID:6269117, PMID:6575958, PMID:6590967, PMID:7873286, PMID:12645653, PMID:19787792, PMID:21519327, PMID:22282976, PMID:23144859, PMID:24136885, PMID:26320182, PMID:28196595, PMID:29334376

Comments: Anecdotal: Cell line where the MET (MNNG-HOS transforming) oncogene was first identified (PubMed=6590967)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MNNG/HOS Cl #5

Synonyms: MNNG/HOS, MNNG-HOS, MNNG HOS, HOS-MNNG, HOS/MNNG, MNNGHOS, MNNG-HOS (Cl#5), MNNG/HOS Clone F-5, MNNG, R-1059-D, TE85, Te85, TE-85, HOS-TE85, Hos TE-85, HOS TE 85, HOS TE85, HOS (TE85), HOS(TE85), HOS (TE85, Clone F5), MNNG-HOS (TE 85, clone F-5), TE-85 clone F-5, HOS-Te85, TE 85.T, TE 85 ClF-5, HOS-TE85 clone 5, TE-85 clone 5

Cross References: BTO:BTO_0005416, CLO:CLO_0003796, CLO:CLO_0007813, CLO:CLO_0007814, EFO:EFO_0002866, MCCL:MCC:0000334, CLDB:cl1703, CLDB:cl1704, CLDB:cl1705, CLDB:cl3510, ATCC:CRL-1547, ATCC:CRL-7734, ATCC:CRL-7735, cancercelllines:CVCL_0439, CCRID:3101HUMTCHu167, CCRID:5301HUM-KCB16037YJ, ChEMBL-Cells:CHEMBL3307282, ChEMBL-Targets:CHEMBL614038, CLS:300289, Cosmic:1044084, Cosmic:1074402, Cosmic:1529901, Cosmic:2301584, ECACC:87070201, GEO:GSM879219, GEO:GSM1915008, GEO:GSM1915009, GEO:GSM1915010, GEO:GSM1915011, GEO:GSM1915025, GEO:GSM1915026, GEO:GSM1915027, GEO:GSM1915028, GEO:GSM1915029, GEO:GSM2635307, GEO:GSM2635308, IARC_TP53:25022, KCB:KCB 2016037YJ, KCLB:21543, Progenetix:CVCL_0439, PubChem_Cell_line:CVCL_0439, Wikidata:Q54906271

ID: CVCL_0439

Hierarchy: cvcl_0312

Record Creation Time: 20220427T220816+0000

Record Last Update: 20260905T181201+0000

Ratings and Alerts

No rating or validation information has been found for MNNG/HOS Cl #5.

Warning: Discontinued: ATCC; CRL-7735
Anecdotal: Cell line where the MET (MNNG-HOS transforming) oncogene was first identified (PubMed=6590967)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project. Warning: Discontinued: ATCC; CRL-7734
Anecdotal: Cell line where the MET (MNNG-HOS transforming) oncogene was first identified (PubMed=6590967)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Li H, et al. (2026) Tumor Extracellular Vesicles lncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A-Dependent hnRNPA2B1/COX-2 Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e19490.

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. Cancer research, 86(9), 2161.

Ren Z, et al. (2026) MAT2A enhances PARN transcription via SRF to accelerate glycolysis and drive malignant progression in osteosarcoma. Communications biology, 9(1), 241.

Wang J, et al. (2026) Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. Science progress, 109(2), 368504261464856.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. Cell reports. Medicine, 6(3), 101977.

Ucci A, et al. (2025) Human osteosarcoma cell secretome impairs neonatal mouse calvarial osteogenic cells functions and modifies the nanoparticles-derived protein profile. Life sciences, 379, 123837.

Jing D, et al. (2025) Transketolase promotes osteosarcoma progression through the YY1-PAK4 axis. The FEBS journal, 292(7), 1798.

Ren J, et al. (2024) Augmented drug resistance of osteosarcoma cells within decalcified bone matrix scaffold: The role of glutamine metabolism. International journal of cancer, 154(9), 1626.

Zheng J, et al. (2024) Tumor mitochondrial oxidative phosphorylation stimulated by the nuclear receptor ROR?? represents an effective therapeutic opportunity in osteosarcoma. Cell reports. Medicine, 5(5), 101519.

Takemoto A, et al. (2022) Targeting Podoplanin for the Treatment of Osteosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(12), 2633.

Li HB, et al. (2022) METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma. EBioMedicine, 82, 104142.

Ponzetti M, et al. (2022) Effects of osteoblast-derived extracellular vesicles on aggressiveness, redox status and mitochondrial bioenergetics of MNNG/HOS osteosarcoma cells. Frontiers in oncology, 12, 983254.

Tang W, et al. (2022) Vascular Niche Facilitates Acquired Drug Resistance to c-Met Inhibitor in Originally Sensitive Osteosarcoma Cells. Cancers, 14(24).

Rathore R, et al. (2021) Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. Cell reports, 34(4), 108678.

Klangjorhor J, et al. (2020) Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment. International journal of cancer, 146(12), 3397.

Bernardini G, et al. (2018) Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma. Journal of cellular physiology, 233(6), 4961.